EUVIMEDEUVIMED entdecken
Crossref

Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas

Lingling Zheng iD, Xu Yang, Jun Liu, Guanyun Wang iD, Zi Ang Zhou, Yanfeng Xu, Jianhua Gong iD, Jigang Yang

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Lingling Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, China. Hauptthemen laut MEDLINE: Zirconium, Neuroblastoma, Radiopharmaceuticals, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed and refractory high-risk neuroblastoma (NBL) patients have limited treatment options and a poor prognosis, highlighting the urgent need for novel targeted therapies. This study evaluates the GD2-targeting PET imaging agent [89Zr]Zr-DFO-hu3F8 and the radioimmunotherapy agent [225Ac]Ac-DOTA-hu3F8 in NBL animal models. The GD2 overexpressing IMR32 tumor was assessed by using [89Zr]Zr-DFO-hu3F8 PET imaging to confirm targeting efficacy. The safety and therapeutic efficacy of [225Ac]Ac-DOTA-hu3F8 were evaluated in GD2-positive NBL xenografts. ImmunoPET revealed the high and sustained uptake of [89Zr]Zr-DFO-hu3F8 in IMR32 tumors compared to the [89Zr]Zr-DFO-IgG control group. In vitro biodistribution analysis showed that a tumor uptake was 58.47 ± 3.64%ID/g at 168 h post-injection. A single dose of [225Ac]Ac-DOTA-hu3F8 treatment significantly suppressed tumor growth, with most tumors (4/5) achieving complete remission at medium and high doses (11.1 and 18.5 kBq). Overall, our findings demonstrate that alpha-targeted therapy based on hu3F8 holds significant potential as a promising curative treatment strategy for NBL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZirconiumNeuroblastomaRadiopharmaceuticalsAntineoplastic AgentsAnimalsHumansMiceRadioisotopesCell Line, TumorPositron-Emission TomographyActiniumFemaleTissue DistributionTheranostic NanomedicineXenograft Model Antitumor AssaysMice, NudeRadioimmunotherapyGangliosides

Substanzen

ZirconiumRadioisotopesZirconium-89ganglioside, GD2ActiniumActinium-225RadiopharmaceuticalsAntineoplastic AgentsGangliosides

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, China.
  • Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

ORCID-Profile: Lingling Zheng, Guanyun Wang, Jianhua Gong

Förderung

  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Zheng, L., Yang, X., Liu, J., Wang, G., Zhou, Z. A., Xu, Y., Gong, J., & Yang, J. (2025). Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02837

Vancouver

Zheng L, Yang X, Liu J, Wang G, Zhou ZA, Xu Y, et al. Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02837

BibTeX
@article{Zheng2025,
  author = {Zheng, Lingling and Yang, Xu and Liu, Jun and Wang, Guanyun and Zhou, Zi Ang and Xu, Yanfeng and Gong, Jianhua and Yang, Jigang},
  title = {Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02837}
}
Kostenlos starten →